Hilda Razzaghi

Hilda Razzaghi

Auto-generated profile, based on publicly available information

Hilda Razzaghi

Immunization Services Division, National Center for Immunization and Respiratory Diseases, CDC, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2020 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Closed access
SBStephanie Bialek
Stephanie Bialek
EBEllen Boundy
Ellen Boundy
VBVirginia Bowen
Virginia Bowen
NCNancy Chow
Nancy Chow
ACAmanda Cohn
Amanda Cohn
ESErin Sauber-Schatz
Erin Sauber-Schatz
Globally, approximately 170,000 confirmed cases of coronavirus disease 2019 (COVID-19) caused by the 2019 novel coronavirus (SARS-CoV-2) have been reported, including an estimated 7,000 deaths in approximately 150 countries (1). On March 11, 2020, the World Health Organization declared the COVID-19 outbreak a pandemic (2). Data from China have indicated that older adults, particularly those with serious underlying health conditions, are at higher risk for severe COVID-19-associated illness and death than are younger persons (3). Although the majority of reported COVID-19 cases in China were mild (81%), approximately 80% of deaths occurred among adults aged ≥60 years; only one (0.1%) death occurred in a person aged ≤19 years (3). In this report, COVID-19 cases in the United States that occurred during February 12-March 16, 2020 and severity of disease (hospitalization, admission to intensive care unit [ICU], and death) were analyzed by age group. As of March 16, a total of 4,226 COVID-19 cases in the United States had been reported to CDC, with multiple cases reported among older adults living in long-term care facilities (4). Overall, 31% of cases, 45% of hospitalizations, 53% of ICU admissions, and 80% of deaths associated with COVID-19 were among adults aged ≥65 years with the highest percentage of severe outcomes among persons aged ≥85 years. In contrast, no ICU admissions or deaths were reported among persons aged ≤19 years. Similar to reports from other countries, this finding suggests that the risk for serious disease and death from COVID-19 is higher in older age groups.

18 June 2021 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Open access
HRHilda Razzaghi
Hilda Razzaghi
MMMehreen Meghani
Mehreen Meghani
CPCassandra Pingali
Cassandra Pingali
BCBradley Crane
Bradley Crane
ANAllison Naleway
Allison Naleway
SPSuchita A Patel
Suchita A Patel
As of May 2021, 16% of pregnant people identified in CDC’s Vaccine Safety Datalink had received ≥1 dose of a COVID-19 vaccine during pregnancy in the U.S. Vaccination was lowest among Hispanic people (12%), non-Hispanic Black people (6%), and people aged 18–24 years (6%), and highest among non-Hispanic Asian people (25%) and people aged 35–49 years (23%).

2 October 2020 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Closed access
HRHilda Razzaghi
Hilda Razzaghi
KKKatherine E. Kahn
Katherine E. Kahn
CBCarla L. Black
Carla L. Black
MLMegan C. Lindley
Megan C. Lindley
TJTara C. Jatlaoui
Tara C. Jatlaoui
WWWalter W. Williams
Walter W. Williams
This report describes influenza and Tdap vaccination coverage among pregnant women during the 2019–20 influenza season.

29 September 2023 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Open access
HRHilda Razzaghi
Hilda Razzaghi
KKKatherine E. Kahn
Katherine E. Kahn
KCKayla Calhoun
Kayla Calhoun
EGEmma Garacci
Emma Garacci
TSTami H. Skoff
Tami H. Skoff
CBCarla L. Black
Carla L. Black
This report describes influenza, Tdap, and COVID-19 vaccination coverage and hesitancy among pregnant people.

24 July 2020 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Closed access
HRHilda Razzaghi
Hilda Razzaghi
YWYan Wang
Yan Wang
HLHua Lu
Hua Lu
KMKatherine E. Marshall
Katherine E. Marshall
NDNicole F. Dowling
Nicole F. Dowling
KGKurt J. Greenlund
Kurt J. Greenlund
This report describes U.S. county-level prevalence estimates of select underlying medical conditions that are associated with higher risk for severe illness from COVID-19.

6 November 2017 in Cancer
Verified
Journal Article
Open access
PDF file
HRHilda Razzaghi
Hilda Razzaghi
MSMona Saraiya
Mona Saraiya
TTTrevor D. Thompson
Trevor D. Thompson
JHJane Henley
Jane Henley
LVLaura Viens
Laura Viens
RWReda Wilson
Reda Wilson
BACKGROUND: Human papillomavirus (HPV) vaccines can potentially prevent greater than 90% of cervical and anal cancers as well as a substantial proportion of vulvar, vaginal, penile, and oropharyngeal cancers caused by certain HPV types. Because more than 38,000 HPV‐associated cancers are diagnosed annually in the United States, current studies are needed to understand how relative survival varies for each of these cancers by certain demographic characteristics, such as race and age.METHODS: The authors examined high‐quality data from 27 population‐based cancer registries covering approximately 59% of the US population. The analyses were limited to invasive cancers that were diagnosed during 2001 through 2011 and followed through 2011 and met specified histologic criteria for HPV‐associated cancers. Five‐year relative survival was calculated from diagnosis until death for these cancers by age, race, and sex.RESULTS: The 5‐year age‐standardized relative survival rate was 64.2% for cervical carcinomas, 52.8% for vaginal squamous cell carcinomas (SCCs), 66% for vulvar SCCs, 47.4% for penile SCCs, 65.9% for anal SCCs, 56.2% for rectal SCCs, and 51.2% for oropharyngeal SCCs. Five‐year relative survival was consistently higher among white patients compared with black patients for all HPV‐associated cancers across all age groups; the greatest differences by race were observed for oropharyngeal SCCs among those aged <60 years and for penile SCCs among those ages 40 to 49 years compared with other age groups.CONCLUSIONS: There are large disparities in relative survival among patients with HPV‐associated cancers by sex, race, and age. HPV vaccination and improved access to screening (of cancers for which screening tests are available) and treatment, especially among groups that experience higher incidence and lower survival, may reduce disparities in survival from HPV‐associated cancers. Cancer 2018;124:203‐211. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.